Evidence map›Paper›PMID 40284921›Full record

ArticleViruses2025

Temporal Trends in HIV-1 Subtypes and Antiretroviral Drug Resistance Mutations in Istanbul, Türkiye (2021-2024): A Next-Generation Sequencing Study.

Murat Yaman, Begüm Saran Gülcen, Kübra Özgüler, Muammer Osman Köksal, Serap Demir Tekol, Arzu İlki

Abstract read
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Murat YamanMedical Microbiology, Marmara University Pendik Research and Training Hospital, Istanbul 34899, Türkiye.ORCID 0000-0002-4488-0826
Begüm Saran GülcenMedical Microbiology, Fatih Sultan Mehmet Research and Training Hospital, Istanbul 34752, Türkiye.ORCID 0000-0003-4367-0496
Kübra ÖzgülerMedical Microbiology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul 34865, Türkiye.ORCID 0000-0001-5139-1898
Muammer Osman KöksalDepartment of Medical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34093, Türkiye.ORCID 0000-0001-8411-2795
Serap Demir TekolMedical Microbiology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul 34865, Türkiye.ORCID 0000-0002-6525-1818
Arzu İlkiMedical Microbiology, Marmara University Pendik Research and Training Hospital, Istanbul 34899, Türkiye.ORCID 0000-0003-3887-7003

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HIV-1 genotyping and drug resistance tests are routinely performed in virology laboratories in some countries, aiding clinical management. In Istanbul, between January 2021 and March 2024, plasma samples from 1029 HIV-1-infected patients were analyzed using the NGS method, and mutation and drug resistance results were retrospectively evaluated alongside demographic data. Subtype B (54.4%) was most frequent in Turkish patients, while Subtype A1 (43.5%) was predominant among foreign nationals. The most common CRFs were CRF02_AG (3.8%) and CRF56_cpx (1.6%). According to the change in detection rates during the study period, Subtype B decreased, and Subtype A increased. The most frequent mutations detected were A62V (38.7%) and M184V (22.4%) for NRTIs; E138A (55.5%) and E138G (11.5%) for NNRTIs; M46I (33.3%) and M46L (25%) for PIs; and E92Q and G for INIs (total rate: 35.2%). Darunavir/ritonavir had the highest sensitivity rate, while resistance rates for NNRTIs and INIs increased over time. We anticipate that this study, in which we evaluate the routine use of an FDA-approved NGS kit alongside integrated bioinformatics data analysis and automated reporting software for the first time in Türkiye, will contribute to both national and international molecular epidemiological data and public health strategies by providing reliable results that align with international standarts.

Indexed as

Anti-HIV AgentsDrug Resistance, ViralHIV-1HIV InfectionsMutationAdultFemaleGenotypeHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedRetrospective StudiesTurkeyYoung AdultAnti-HIV Agentsantiretroviral drug resistanceHIV-1 mutations and subtypeshuman immunodeficiency virusnext-generation sequencing

Identifiers

PMID40284921
PMCPMC12031039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.